GSN Analysis

What does Merck’s pulled £1bn plan actually mean for UK life sciences?
The big pharma firm’s decision is about more than real estate as negotiations with the government hang in the balance
The big pharma firm’s decision is about more than real estate as negotiations with the government hang in the balance